New RAS-Targeted Drug Approved for Pancreatic Cancer

Adults whose pancreatic cancer has not responded to earlier treatment now have a first RAS-inhibitor option.

Updated on Nov. 7, 2026 in Cancer

Laboratory bench with a row of unlabeled glass flasks holding amber liquid, and a steel centrifuge rotor softly blurred behind them.
The FDA has approved Rasonque, generically daraxonrasib, for adults with pancreatic cancer who did not respond to earlier treatment, the first RAS inhibitor cleared for the disease. AI Illustration. Upload story photo >

The FDA has approved Rasonque, generically known as daraxonrasib, for pancreatic cancer patients, with the approval announced in August 2026. The drug is authorized only for second-line patients who have not responded to a previous treatment.

Why it matters

Rasonque is the first RAS inhibitor approved for pancreatic cancer, a field where mutations in the RAS family of genes drive over 90% of cases. For patients whose earlier treatments have stopped working, the approval adds a targeted option built around the disease's underlying genetic driver.

The approval followed positive results from large-scale clinical trials, including a trial at the Karmanos Cancer Institute in Detroit. The source does not provide the trial's sample size or measured effect size, so the strength of the benefit cannot be characterized further.

The players

Revolution Medicines

A California-based drug developer that manufactures Rasonque, a targeted therapy aimed at RAS gene mutations.

Karmanos Cancer Institute

A Detroit cancer research center that served as a trial site for the clinical results supporting Rasonque's approval.

Pancreatic Cancer Action Network

An Iowa-based advocacy organization focused on pancreatic cancer research, awareness, and patient support.

The details

Rasonque specifically targets mutations in the RAS family of genes, which control cell division and growth. Because these mutations drive over 90% of pancreatic cancer, a drug aimed at them addresses the disease at its genetic root rather than at general tumor behavior. The FDA limited the approval to adults who have not responded to previous treatment.

Timeline

  1. August 2026: FDA approved Rasonque for pancreatic cancer patients.

  2. November 7, 2026: Article published about the approval.

Health Landscape

Rasonque is the first RAS inhibitor approved for pancreatic cancer, opening a targeted option where treatment has long relied on broad chemotherapy. Because RAS mutations drive over 90% of these tumors, the approval moves the field toward therapies matched to the disease's genetic driver.

If you or a family member has pancreatic cancer that has not responded to earlier treatment, this approval is worth raising with your oncologist as a possible option. Whether a RAS-targeted therapy fits depends on individual factors, so the conversation belongs with your treating physician.

The takeaway

Targeting the RAS genes that drive most pancreatic cancers marks a shift toward treatments matched to the disease's genetic makeup. Ask your oncologist whether genetic or molecular testing of your tumor is appropriate, since that information can determine which targeted options may apply.

Further reading

For broader context on how targeted treatments are changing care, see our Cancer coverage.

Source note: This article includes information reported by Thealpenanews.